Jens Eberlein

Jens Eberlein

Company: LUMICKS

Job title: Technical Lead, Immuno-Oncology


The In-Vitro Measure of Cell Avidity Between Tumor-Effector Pairs, Not Affinity, Predicts Optimal Anti-Tumor Response In-Vivo 12:45 pm

• We present data discussing how increased specific avidity, those TCR’s with strongest antigen binding with the lowest background, correlate with improved TCR function in-vitro and in-vivo • A novel assay where cross-reactivity between TCRs and target can be quickly quantified • How avidity has shown a correlation with improved tumor control in in-vivo murine…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.